These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 20840674)
1. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674 [TBL] [Abstract][Full Text] [Related]
2. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523 [TBL] [Abstract][Full Text] [Related]
3. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937 [TBL] [Abstract][Full Text] [Related]
5. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632 [TBL] [Abstract][Full Text] [Related]
6. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer]. Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637 [TBL] [Abstract][Full Text] [Related]
7. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240 [TBL] [Abstract][Full Text] [Related]
8. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488 [TBL] [Abstract][Full Text] [Related]
9. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774 [TBL] [Abstract][Full Text] [Related]
10. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623 [TBL] [Abstract][Full Text] [Related]
11. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338 [TBL] [Abstract][Full Text] [Related]
12. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003 [TBL] [Abstract][Full Text] [Related]
13. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma. Guerra A; Zeppa P; Bifulco M; Vitale M Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056 [TBL] [Abstract][Full Text] [Related]
14. RET/PTC rearrangement occurring in primary peritoneal carcinoma. Flavin R; Jackl G; Finn S; Smyth P; Ring M; O'Regan E; Cahill S; Unger K; Denning K; Jinghuan Li ; Aherne S; Tallini G; Gaffney E; O'Leary JJ; Zitzelsberger H; Sheils O Int J Surg Pathol; 2009 Jun; 17(3):187-97. PubMed ID: 19147513 [TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863 [TBL] [Abstract][Full Text] [Related]
16. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Nikiforova MN; Ciampi R; Salvatore G; Santoro M; Gandhi M; Knauf JA; Thomas GA; Jeremiah S; Bogdanova TI; Tronko MD; Fagin JA; Nikiforov YE Cancer Lett; 2004 Jun; 209(1):1-6. PubMed ID: 15145515 [TBL] [Abstract][Full Text] [Related]
17. Radiation induced thyroid cancer: fundamental and applied aspects. Tronko M; Bogdanova T; Voskoboynyk L; Zurnadzhy L; Shpak V; Gulak L Exp Oncol; 2010 Sep; 32(3):200-4. PubMed ID: 21403618 [TBL] [Abstract][Full Text] [Related]
19. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma]. Zhu XL; Zhou XY; Zhu XZ Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547 [TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Brzeziańska E; Karbownik M; Migdalska-Sek M; Pastuszak-Lewandoska D; Włoch J; Lewiński A Mutat Res; 2006 Jul; 599(1-2):26-35. PubMed ID: 16483615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]